When science is not enough – a risk/benefit profile of thiomersal-containing vaccines

Author： Clements C John   McIntyre Peter B  

Publisher： Informa Healthcare

ISSN： 1474-0338

Source： Expert Opinion on Drug Safety, Vol.5, Iss.1, 2006-01, pp. : 17-29

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The benefit-risk balance of thiomersal-containing vaccines remains overwhelmingly positive

By  

Inpharma, Vol. 1, Iss. 1376, 2003-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite

EMEA supports safety of thiomersal-containing vaccines

By  

Inpharma, Vol. 1, Iss. 1432-1433, 2004-01 ,pp. : 21-21

Adis International

Access to resources Recommend Favorite

Cardiovascular Risk-Benefit Profile of Sibutramine

By Scheen A.J.  

American Journal of Cardiovascular Drugs, Vol. 10, Iss. 5, 2010-10 ,pp. : 321-334

Adis International

Access to resources Recommend Favorite

Thiomersal in Vaccines: Balancing the Risk of Adverse Effects with the Risk of Vaccine-Preventable Disease

By Mark Bigham   Ray Copes  

Drug Safety, Vol. 28, Iss. 2, 2005-01 ,pp. : 89-101

Adis International

Access to resources Recommend Favorite

Statin Treatment and the Natural History of Atherosclerotic-Related Diseases: Pathogenic Mechanisms and the Risk-Benefit Profile

By  

Current Pharmaceutical Design, Vol. 10, Iss. 4, 2004-02 ,pp. : 425-432

Bentham Science Publishers

Access to resources Recommend Favorite